Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Cardiol. Jul 26, 2013; 5(7): 247-253
Published online Jul 26, 2013. doi: 10.4330/wjc.v5.i7.247
Table 1 Baseline characteristics of study population: Clinical, laboratory and imaging data n (%)
Variablesn = 86
Male gender67 (77.9)
Age (yr)55.87 ± 11.85
Background diseases
Stage-1 (malignant) hypertension14 (16.3)
Stage-2 hypertension65 (75.6)
Diabetes mellitus34 (39.5)
Smoking61 (70.9)
Clinical features of left ventricular dysfunction23 (26.7)
Left ventricular hypertrophy29 (33.7)
Coronary artery disease72 (83.7)
Blood pressure
Systolic (mmHg)170.15 ± 20.10
Diastolic (mmHg)98.38 ± 10.55
Antihypertensive drugs (n)3.07 ± 0.69
Indication criteria
Hypertension resistant to standard medication71 (82.6)
Renal bruit53 (61.6)
Serum creatinine (mg/dL)20 (23.3)
Stenosis
Bilateral23 (26.7)
Coronary angiography
Single vessel disease25 (29.1)
Double vessel disease14 (16.3)
Triple vessel disease28 (32.6)
Normal vessel19 (22.1)
Table 2 Blood pressure, antihypertensive medication, serum creatinine and glomerular filtration rate initial vs follow-up measurements
Time of follow-upmean ± SDP value
Systolic blood pressure (mmHg)170.15 ± 20.10< 0.0001
Baseline
1 mo146.60 ± 17.32
6 mo144.23 ± 18.19
Diastolic blood pressure (mmHg)98.38 ± 10.55< 0.0001
Baseline
1 mo89.88 ± 9.22
6 mo88.26 ± 9.79
Antihypertensive drugs (n)3.07 ± 0.69< 0.0001
Baseline
1 mo2.37 ± 0.84
6 mo2.25 ± 0.94
Serum creatinine (mg/dL)1.21 ± 0.660.964
Baseline
48 h1.29 ± 0.88
1 mo1.33 ± 1.27
6 mo1.21 ± 0.79
GFR estimation (mL/min)65.71 ± 25.200.546
Baseline
6 mo66.68 ± 25.03
Table 3 Levels of sIL-2R, alanine aminotransferase, and hepatitis B virus DNA in the sera of patients with chronic HBV infection (mean ± SD)
Group1nmean ± SDP value
Age (yr)0.51
A2656.81 ± 13.87
B4954.80 ± 11.55
Initial systolic BP (mmHg)0.01
A26179.31 ± 20.32
B49166.00 ± 18.76
Initial diastolic BP (mmHg)0.04
A26101.92 ± 10.90
B4996.79 ± 10.14
Initial mean BP (mmHg)0.01
A26141.00 ± 17.73
B49129.00 ± 16.76
No. of medications0.01
A263.26 ± 0.77
B492.87 ± 0.57
Creatinine (mg/dL)0.07
A261.38 ± 0.48
B491.11 ± 0.66
Diameter of stent0.23
A265.76 ± 0.94
B496.05 ± 0.98
Percent of renal artery stenosis (RAS)0.05
A2687.65 ± 7.71
B4983.79 ± 8.40
GFR (mL/min)0.01
A2654.03 ± 24.22
B4972.97 ± 25.43
Duration of HT (yr)0.55
A264.00 ± 3.96
B493.40 ± 3.32
Table 4 Clinical features of resistant hypertensive group: Responsive vs unresponsive to percutaneous transluminal renal artery n (%)
Group AGroup BP value
n = 26n = 49
Male gender24 (92.3)33 (67.3)0.016
Smoker22 (84.6)33 (67.4)0.1
Ischemic heart disease21 (80.8)35 (71.4)0.376
Diabetes mellitus8 (30.8)19 (38.8)0.49
C/f of LVF5 (19.2)11 (22.4)0.746
Smoking22 (84.6)33 (67.4)0.1
Renal bruit20 (76.9)29 (59.2)0.124
Refractory HT23 (88.5)37 (75.5)0.182
LVH14 (53.9)14 (28.6)0.031
LAD19 (73.1)34 (69.4)0.733
TVD12 (46.2)13 (26.5)0.08
Renal artery stenosisUnilateral RAS15 (57.7)40 (81.6)0.026
(unilat vs bilat)Bilateral RAS11 (42.3)9 (18.4)
LMCA diseaseAbsent23 (88.5)47 (95.9)0.218
Present3 (11.5)2 (4.1)
Table 5 Multivariate analysis: The independent predictors for poor blood pressure response after percutaneous transluminal renal artery
VariablesUnivariateP valueMultivariate analysis
95%CI
P valueβExpβ
Male sex0.020.0461.7976.0321.028–35.380
High mean SBP0.01NS
High mean DBP0.05NS
High mean BP0.090.013-0.0440.9570.925–0.991
Low GFR (< 60 mL/min)0.010.0151.3773.9651.308–12.020
LVH0.03NS
Drugs (n)0.01NS
Bilateral vs unilateral RAS0.02NS
Percent of stenosis0.06NS
Presence of TVD0.09NS
Constant2.36510.65